Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7445339 | 0.86 | — | — | |
| SCHEMBL9049373 | 0.85 | CHRM2 (0.34) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL3317402 | 0.85 | CHRM2 (0.34) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL5168165 | 0.75 | CHRNA7 (0.42) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2496607 | 0.75 | CHRNA7 (0.42) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL1058409 | 0.75 | CHRNA7 (0.42) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL8758623 | 0.65 | — | — | |
| SCHEMBL9091935 | 0.65 | — | — | |
| SCHEMBL8758466 | 0.65 | — | — | |
| SCHEMBL2608730 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2119716-A1 | AZA-BRIDGED-RING COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-0261763-B1 | Novel bridged bicyclic N-heterocycles | BEECHAM GROUP PLC (GB) | 1994-02-09 | — | — | EP | disclosed |
| US-4968691-A | TREATMENT AND PREVENTION OF DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1990-11-06 | — | — | US | disclosed |
| US-4870081-A | DEMENTIA | BEECHAM GROUP P.L.C. (GB) | 1989-09-26 | — | — | US | disclosed |
| EP-0261763-A1 | Novel bridged bicyclic N-heterocycles | BEECHAM GROUP PLC (GB) | 1988-03-30 | — | — | EP | disclosed |
| EP-0257741-A2 | Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | CHRM2 3/4885CHRM4 5/4885CHRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.